GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (OSTO:AZN) » Definitions » Cyclically Adjusted Price-to-FCF

AstraZeneca (OSTO:AZN) Cyclically Adjusted Price-to-FCF : 65.93 (As of May. 24, 2024)


View and export this data going back to 1999. Start your Free Trial

What is AstraZeneca Cyclically Adjusted Price-to-FCF?

As of today (2024-05-24), AstraZeneca's current share price is kr1695.00. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was kr25.71. AstraZeneca's Cyclically Adjusted Price-to-FCF for today is 65.93.

The historical rank and industry rank for AstraZeneca's Cyclically Adjusted Price-to-FCF or its related term are showing as below:

OSTO:AZN' s Cyclically Adjusted Price-to-FCF Range Over the Past 10 Years
Min: 12.25   Med: 25.15   Max: 73.79
Current: 65.78

During the past years, AstraZeneca's highest Cyclically Adjusted Price-to-FCF was 73.79. The lowest was 12.25. And the median was 25.15.

OSTO:AZN's Cyclically Adjusted Price-to-FCF is ranked worse than
72.12% of 312 companies
in the Drug Manufacturers industry
Industry Median: 33.315 vs OSTO:AZN: 65.78

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share data for the three months ended in Mar. 2024 was kr5.880. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is kr25.71 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for AstraZeneca's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Cyclically Adjusted Price-to-FCF Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.17 48.06 60.81 62.36 57.15

AstraZeneca Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.90 62.58 58.91 57.15 56.63

Competitive Comparison of AstraZeneca's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.



AstraZeneca Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

AstraZeneca's Cyclically Adjusted Price-to-FCF for today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/ Cyclically Adjusted FCF per Share
=1695.00/25.71
=65.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=5.88/131.6000*131.6000
=5.880

Current CPI (Mar. 2024) = 131.6000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 4.967 99.800 6.550
201409 8.659 100.000 11.395
201412 8.287 99.900 10.917
201503 -7.748 99.600 -10.237
201506 2.849 100.100 3.746
201509 8.009 100.200 10.519
201512 0.242 100.400 0.317
201603 5.847 100.400 7.664
201606 -5.383 101.000 -7.014
201609 2.999 101.500 3.888
201612 9.592 102.200 12.351
201703 -2.091 102.700 -2.679
201706 -0.555 103.500 -0.706
201709 11.948 104.300 15.075
201712 2.947 105.000 3.694
201803 -3.083 105.100 -3.860
201806 -2.042 105.900 -2.538
201809 1.411 106.600 1.742
201812 12.936 107.100 15.895
201903 -8.406 107.000 -10.339
201906 -0.688 107.900 -0.839
201909 5.639 108.400 6.846
201912 7.112 108.500 8.626
202003 -1.777 108.600 -2.153
202006 0.447 108.800 0.541
202009 7.539 109.200 9.085
202012 7.962 109.400 9.578
202103 9.489 109.700 11.383
202106 3.434 111.400 4.057
202109 6.119 112.400 7.164
202112 4.073 114.700 4.673
202203 17.580 116.500 19.859
202206 4.535 120.500 4.953
202209 12.730 122.300 13.698
202212 12.267 125.300 12.884
202303 11.168 126.800 11.591
202306 8.526 129.400 8.671
202309 15.881 130.100 16.064
202312 9.381 130.500 9.460
202403 5.880 131.600 5.880

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AstraZeneca  (OSTO:AZN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


AstraZeneca Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca (OSTO:AZN) Business Description

Industry
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

AstraZeneca (OSTO:AZN) Headlines

From GuruFocus